LGALS3 and liver disorder: It contains oligosaccharide chains containing galactose residues, binds to Gal‐3, and inhibits function of Gal‐3.[581] The safety and pharmacokinetics of belapectin have been confirmed in a randomized clinical study in NASH participants with bridging fibrosis.[582] However, in a phase IIb, randomized trial assessing belapectin in patients with NASH, cirrhosis, and portal hypertension, belapectin was found to be safe but not associated with significant reduction in fibrosis.